Type 2 Diabetes Drugs Linked to Cancer

 Posted on June 17, 2014 in Defective Drugs & Treatments

A recent study, published by AdverseEvents.com, has found that a new class of diabetes treatment drugs may have serious side effects and are not necessarily being touted by the drug manufacturer or the doctors administering them. In April, AdverseEvents suggested a comparable safety research (CSR) study to offer a counterpoint to the report issued by the drug manufacturer. AdverseEvents released a publication using the proposed CSR framework regarding Type 2 Diabetes medication and found that while the drugs can be effective, they may have highly adverse and narrowly published side effects.

The drugs included in the study are GLP–1 Agonists, DPP–4 Inhibitors, and SGLT–2 Inhibitors. All drugs are manufactured by industry heavy-hitters, and while each has been tested in the lab for adverse side effects, none were formally analyzed by the drug company once they were dispersed for wide use. AdverseEvents CEO, Brian Overstreet, told DrugWatch.com that the only way to truly track the potential negative side effects of a drug is to monitor its effect on real patients in the real world.

The report found that these new Type 2 Diabetes drugs are linked to pancreatic cancer in users. Both GLP–1 receptor agonists and DPP–4 inhibitors have been linked to pancreatitis or pancreatic cancer. "Bydureon and Byetta may be safer choices than Victoza within the GLP–1 inhibitor class," DrugWatch.com suggested. However, SGLT–2 inhibitors were associated with increased risk of urinary infections, renal and gallbladder issues, and bladder cancer.

The Center for Disease Control notes that there are nearly 26 million people in the U.S. currently living with Diabetes, affecting more than eight percent of the national population. But the disease is not just an American problem. An estimated 350 million people globally live with Type 1 or 2 Diabetes.

If you have been negatively affected by a Diabetes treatment in Illinois, you may be eligible for compensation. Do not go through it alone. Contact Newland & Newland, LLP for a free phone consultation today.